Evidence map›Paper›PMID 35806448›Full record

ArticleInternational journal of molecular sciences2022

Therapeutic Effects of Quetiapine and 5-HT

Yukiko Ochiai, Masayo Fujita, Yoko Hagino, Kazuto Kobayashi, Ryoichi Okiyama, Kazushi Takahashi, Kazutaka Ikeda

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Yukiko OchiaiAddictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan.
Masayo FujitaAddictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan.
Yoko HaginoAddictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan.
Kazuto KobayashiDepartment of Molecular Genetics, Institute of Biomedical Sciences, Fukushima Medical University, Fukushima 960-1295, Japan.
Ryoichi OkiyamaDepartment of Neurology, Tokyo Metropolitan Neurological Hospital, Tokyo 183-0042, Japan.ORCID 0000-0001-6073-7897
Kazushi TakahashiDepartment of Neurology, Tokyo Metropolitan Neurological Hospital, Tokyo 183-0042, Japan.
Kazutaka IkedaAddictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan.ORCID 0000-0001-8342-0278
Tokyo Metropolitan Institute of Medical Science · JPTokyo Metropolitan Neurological Hospital · JPFukushima Medical University · JP

Funding

Astellas Foundation for Research on Metabolic Disorders no numberJapan Society for the Promotion of Science 15H01303Japan Society for the Promotion of Science JP16H06276 [AdAMS]Ministry of Education, Culture, Sports, Science and Technology 25116232Takeda Science Foundation no number
6 · The paper itself

Abstract

Some diseases that are associated with dopamine deficiency are accompanied by psychiatric symptoms, including Parkinson's disease. However, the mechanism by which this occurs has not been clarified. Previous studies found that dopamine-deficient (DD) mice exhibited hyperactivity in a novel environment. This hyperactivity is improved by clozapine and donepezil, which are used to treat psychiatric symptoms associated with dopamine deficiency (PSDD). We considered that DD mice could be used to study PSDD. In the present study, we sought to identify the pharmacological mechanism of PSDD. We conducted locomotor activity tests by administering quetiapine and drugs that have specific actions on serotonin (5-hydroxytryptamine [5-HT]) receptors and muscarinic receptors. Changes in neuronal activity that were induced by drug administration in DD mice were evaluated by examining Fos immunoreactivity. Quetiapine suppressed hyperactivity in DD mice while the 5-HT

Indexed as

Antipsychotic AgentsDopamineQuetiapine FumarateReceptor, Serotonin, 5-HT1ASerotonin 5-HT1 Receptor AgonistsAnimalsMiceSerotoninSerotonin AntagonistsAntipsychotic AgentsDopamineQuetiapine FumarateReceptor, Serotonin, 5-HT1ASerotoninSerotonin 5-HT1 Receptor AgonistsSerotonin Antagonists5-HT1A receptordopamine deficiencydopamine-deficient miceParkinson’s diseasepsychiatric symptoms

Identifiers

PMID35806448
PMCPMC9266854
OpenAlexW4283794329

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.